75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of December 9, 2024 Best responder duration of response was 31.5 months with complete response ongoing as of December 9, 2024 Conference call to discuss results Tuesday, December 10, 2024 4:30 p.m.

ET at https://zoom.us/j/94736340854?pwd=LTBtu2LuvwSb6S6ISuH5yKTDLsI2vt.1 LOS ANGELES, CA, Dec.

10, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that new NXC-201 NEXICART-1 clinical data in relapsed/refractory AL Amyloidosis has been presented at 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California. The updated results include follow-up and clinical data from 3 new NEXICART-1 patients.

“We are encouraged by the updated NXC-201 results being presented by our academic collaborators at ASH 2024. We believe the high percentage of complete responders, combined with the consistent, attractive tolerability profile is critically important in relapsed/refractory AL Amyloidosis. This expanded NXC-201 dataset continues to bolster our leadership in relapsed/refractory AL Amyloidosis, where no drugs are FDA approved today,” said Ilya Rachman, M.

D., Ph.D.

,.